357 related articles for article (PubMed ID: 21745419)
1. Cytokine disturbances in systemic lupus erythematosus.
Jacob N; Stohl W
Arthritis Res Ther; 2011 Jul; 13(4):228. PubMed ID: 21745419
[TBL] [Abstract][Full Text] [Related]
2. From mechanism to therapies in systemic lupus erythematosus.
Paley MA; Strand V; Kim AH
Curr Opin Rheumatol; 2017 Mar; 29(2):178-186. PubMed ID: 28118202
[TBL] [Abstract][Full Text] [Related]
3. [Cytokine blockade - a promising therapeutic option in SLE].
Aringer M; Feierl E; Smolen J
Z Rheumatol; 2008 Jul; 67(4):315-7. PubMed ID: 18491117
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
5. Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.
Idborg H; Oke V
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768756
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
Slight-Webb S; Lu R; Ritterhouse LL; Munroe ME; Maecker HT; Fathman CG; Utz PJ; Merrill JT; Guthridge JM; James JA
Arthritis Rheumatol; 2016 Oct; 68(10):2492-502. PubMed ID: 27059145
[TBL] [Abstract][Full Text] [Related]
7. Treatment of systemic lupus erythematosus: new advances in targeted therapy.
Lo MS; Tsokos GC
Ann N Y Acad Sci; 2012 Jan; 1247():138-52. PubMed ID: 22236448
[TBL] [Abstract][Full Text] [Related]
8. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
Yao Y; Higgs BW; Richman L; White B; Jallal B
Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
[TBL] [Abstract][Full Text] [Related]
9. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
Stohl W
Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
[TBL] [Abstract][Full Text] [Related]
10. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
Clark DN; Markham JL; Sloan CS; Poole BD
Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
[TBL] [Abstract][Full Text] [Related]
12. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.
Lichtman EI; Helfgott SM; Kriegel MA
Clin Immunol; 2012 Jun; 143(3):210-21. PubMed ID: 22525889
[TBL] [Abstract][Full Text] [Related]
14. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes.
López P; Scheel-Toellner D; Rodríguez-Carrio J; Caminal-Montero L; Gordon C; Suárez A
Rheumatology (Oxford); 2014 Dec; 53(12):2249-58. PubMed ID: 24942493
[TBL] [Abstract][Full Text] [Related]
15. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).
Stohl W
Arthritis Res Ther; 2010; 12(2):111. PubMed ID: 20441604
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial drugs inhibit IFNα-enhanced TNFα and STAT4 expression in monocytes: implication for systemic lupus erythematosus.
López P; Rodríguez-Carrio J; Suárez A
Cytokine; 2014 May; 67(1):13-20. PubMed ID: 24680477
[TBL] [Abstract][Full Text] [Related]
17. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Vincent FB; Morand EF; Mackay F
Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
[TBL] [Abstract][Full Text] [Related]
18. Increased interferon-1α, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus.
Fernández Matilla M; Grau García E; Fernández-Llanio Comella N; Chalmeta Verdejo I; Ivorra Cortés J; Castellano Cuesta JA; Román Ivorra JA
Med Clin (Barc); 2019 Sep; 153(6):225-231. PubMed ID: 30795903
[TBL] [Abstract][Full Text] [Related]
19. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
Sanchez-Niño MD; Ortiz A
Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
[TBL] [Abstract][Full Text] [Related]
20. Anti-interferon alpha treatment in SLE.
Kirou KA; Gkrouzman E
Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
